In re HIV Antitrust Litigation
Case Number:
3:19-cv-02573
See also:
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Arnold & Porter
- Ballard Spahr
- Baron & Budd
- Berry Silberberg
- Boies Schiller
- Cahill Gordon
- Crowell & Moring
- Dillingham & Murphy
- Duane Morris
- Faegre Drinker
- Glancy Prongay
- Goodwin Procter
- Hagens Berman
- Hangley Aronchick
- Hausfeld LLP
- Hilliard & Shadowen
- Holland & Knight
- Kanner & Whiteley
- Kellogg Hansen
- Kenny Nachwalter
- Kessler Topaz
- Kirkland & Ellis
- Law Offices of Francis O. Scarpulla
- Lockridge Grindal
- Milberg Coleman
- Miller Shah LLP
- Morrison Foerster
- NastLaw
- Nussbaum Law Group
- Polsinelli PC
- Pritzker Levine
- Proskauer Rose
- Radice Law Firm
- Rivero Mestre
- Robins Kaplan
- Spector Roseman
- Sperling & Slater
- Whatley Kallas
- White & Case
- Wiggin & Dana
- Wilson Sonsini
- Zelle LLP
Companies
- Aetna Inc.
- Akros Pharma Inc.
- Albertsons Cos. Inc.
- Amneal Pharmaceuticals Inc.
- Blue Cross Blue Shield Association
- BlueCross BlueShield of South Carolina
- Bristol-Myers Squibb Co.
- Centene Corp.
- Cipla Ltd.
- CVS Health Corp.
- Florida Blue
- Fraternal Order of Police
- Gilead Sciences Inc.
- Health Care Service Corp.
- Humana Inc.
- Japan Tobacco
- Johnson & Johnson
- Johnson & Johnson Inc.
- LifeWallet
- Rite Aid Corp.
- Service Employees International Union
- Teva Pharmaceutical Industries Ltd.
- The Kroger Co.
- Viatris Inc.
- Zydus Pharmaceuticals Inc.
Government Agencies
Sectors & Industries:
-
January 14, 2022
Judge Limits Tolling On Retailer Claims In HIV Generics Suit
A California federal judge has trimmed antitrust claims that retailers including Walgreens and CVS filed against Teva over alleged overcharges for HIV drugs, saying any claims stretching back more than four years from their lawsuits are time-barred.
-
January 05, 2022
Teva Urges Judge To Limit Walgreens, CVS Antitrust Claims
Teva Pharmaceuticals urged a California federal judge Wednesday to curb antitrust claims brought by Walgreens, CVS and other retailers alleging that the pharmaceutical giant conspired with rival Gilead to keep generic versions of blockbuster HIV treatments off the market, arguing that some of the retailers' claims are time-barred.
-
November 05, 2021
Bristol-Myers Inks $10M Deal To End Drug Antitrust Claims
Bristol-Myers Squibb has reached a $10 million settlement to escape claims that it conspired with rivals to keep a blockbuster HIV treatment off the market, and both sides are hoping that a California federal judge will preliminarily bless the deal.
-
July 29, 2020
HIV Drug Suit Against Gilead, BMS And Janssen Trimmed
A California federal judge dismissed attempts to revive allegations of an antitrust conspiracy involving Gilead, Bristol-Myers Squibb and Janssen Pharmaceuticals to block generic competition and keep HIV medication prices artificially high in a decision unsealed Wednesday that nevertheless left intact key parts of the complaint.
-
July 16, 2020
Gilead Tries To Shake Antitrust Suit Over Expensive HIV Drugs
Gilead Sciences urged a California federal judge Thursday to nix AIDS activists and consumers' renewed allegations that it engaged in anti-competitive conduct with Bristol-Myers Squibb and Janssen Pharmaceuticals to block generic competition and keep HIV medication prices artificially high, arguing the plaintiffs have failed to properly identify a product market.
-
June 03, 2020
Gilead Can't Shake New HIV Antitrust Complaint, Court Told
Pharmaceutical giants accused of working together to block generic competition for blockbuster HIV treatments are using their latest motion to dismiss to rehash arguments the California federal court has already dealt with, the proposed class said Tuesday.
-
May 05, 2020
New HIV Antitrust Complaint, Same Problems, Gilead Says
Gilead Sciences, Bristol-Myers Squibb Co. and Janssen Pharmaceuticals urged a California federal judge Monday to toss newly rejiggered parts of an antitrust complaint alleging that they conspired to block competition for blockbuster HIV treatments, arguing that none of the failings that doomed part of the original complaint has been fixed.
-
March 04, 2020
Gilead Can't Duck Sweeping Competition Suit Over HIV Drugs
Gilead Sciences and several other drug companies remain mired in a sprawling lawsuit alleging they conspired to block competition for blockbuster HIV treatments, after a California federal judge issued a mixed ruling on their dismissal bids.
-
October 28, 2019
FTC Rips Gilead's 'Erroneous' Argument In HIV Drug Rumble
The Federal Trade Commission has waded into a lawsuit accusing Gilead Sciences Inc. of creating an HIV drug empire by using shadowy deals to block generic competition, assailing the company's argument that only one product market is relevant to the case.
-
September 04, 2019
Gilead Says HIV 'No Generic' Suit Is Baseless
Gilead Sciences Inc. urged a California federal court on Wednesday to toss a suit alleging it created an HIV drug empire using shadowy deals to block generic competition, arguing that its dealings were entirely aboveboard.